Dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Pre-exposure prophylaxis for COVID-19 in adults and adolescents aged 12 years and older and with a body weight of at least 40 kg
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-11-02 A G-BA decision was published.
Project details
- Project no.
- A23-42
- Commission
- Commission awarded on 11.05.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Addendum
Tixagevimab/cilgavimab (pre-exposure prophylaxis of COVID-19) – Addendum to Commission A23-42
Status: Commission completed